Cingulate (NASDAQ:CING) & Abcam (OTCMKTS:ABCZY) Head to Head Survey

Cingulate (NASDAQ:CING) and Abcam (OTCMKTS:ABCZY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Risk and Volatility

Cingulate has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, Abcam has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Valuation & Earnings

This table compares Cingulate and Abcam”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45 million	($3.59)	-1.45
Abcam	$336.37 million	0.00	N/A	N/A	N/A

Abcam has higher revenue and earnings than Cingulate.

Insider & Institutional Ownership

41.3% of Cingulate shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Cingulate and Abcam, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1	0	3	0	2.50
Abcam	0	0	0	0	0.00

Cingulate currently has a consensus target price of $27.33, suggesting a potential upside of 424.63%. Given Cingulate’s stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Abcam.

Profitability

This table compares Cingulate and Abcam’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
Abcam	N/A	N/A	N/A

Summary

Cingulate beats Abcam on 5 of the 9 factors compared between the two stocks.

About Cingulate

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

About Abcam

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.